Opinion: U.S. government must invest more in research around men’s sexual and reproductive health
U.S. research into men’s sexual and reproductive health is lagging despite recent clinical progress. The article spotlights late-stage male contraceptive candidates, FDA approval of long-acting PrEP, rising STI burdens, and proposed NIH budget cuts.
Why it mattersFDA approval of lenacapavir and late-stage NES/T trials indicate near-term contraceptive and PrEP advances.